Eliem Therapeutics
ELYM | NASDAQ
$5.11
-$0.05 (-0.97%)
At close: Oct 02, 2024, 04:00 PM ET
-0.97%
(1D)Rating
Key Statistics
Market Data
Market Cap $342.68M
1D Range
5.00 5.26
52W Range
2.35 11.55
Valuation (TTM)
PE -6.23
PB 1.43
EV/EBITDA -33.97
Valuation (NTM)
Forward PE N/A
Forward PEG -0.55
Price Target N/A
Cash Flow
FCF Yield -15.5%
SBC Adj. FCF Yield -17.9%
SBC Impact -15.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 54.4% |
23.9%
FCF 3Y | 5Y -80.2% |
-7.1%
Returns
ROA -23.4%
ROE -31.8%
ROIC -26.9%
Financial Health
Net Cash
$181.81M
Current Ratio 31.45
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions for conditions characterized by abnormal neuronal excitability. The company aims to fulfill ...
Sector Healthcare
Industry Biotechnology
Employees 9
IPO Date Aug 10, 2021
Website www.eliemtx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ELYM